A Novel Use of Anifrolumab for a Novel Disease.
Аннотация
OBJECTIVE
To explore the potential role of type-I interferon (IFN-I) signaling in autoimmune cytopenias outside the context of systemic lupus erythematosus (SLE), and to evaluate the clinical response to off-label anifrolumab in two patients with fatigue and immune-mediated cytopenias who did not meet established criteria for SLE.
METHODS
We describe two older White male patients with fatigue and autoimmune cytopenias who did not meet established SLE criteria and were refractory to standard immunosuppressants. Both received off-label anifrolumab.
RESULTS
Both patients experienced rapid and sustained improvement in fatigue and resolution of cytopenias following treatment, with continued benefit and no significant adverse effects.
CONCLUSION
These cases suggest IFN-I signaling may underlie autoimmune cytopenias outside classic SLE. The positive response to anifrolumab raises the possibility of an atypical or distinct IFN-mediated autoimmune condition and supports broader investigation of IFN blockade in hematologic autoimmunity.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.